|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Intestinal Disease Research Program, McMaster University, Hamilton, ON, Canada
* To whom correspondence should be addressed. E-mail: perdue{at}mcmaster.ca.
Penetration of the gut epithelial barrier by intact luminal antigen is necessary for immunologically-mediated pathophysiology in the context of food allergy. We investigated if glucagon-like peptide-2 (GLP-2) could affect immediate hypersensitivity and late phase allergic inflammation in a murine model. Mice were sensitized to horseradish peroxidase (HRP); studies were conducted 14 days later. Mice were treated with 5 µg of GLP-2 sc 4h before antigen challenge. For immediate hypersensitivity, jejunal segments in Ussing chambers were challenged by luminal HRP antigen. GLP-2 treatment reduced the uptake of HRP and the antigen-induced secretory response after luminal challenge. GLP-2 appears to reduce macromolecular uptake independent of the CD23 mediated enhanced antigen uptake pathway. For the late phase, mice were gavaged with antigen and 48 h later the function and histology of the jejunum was examined. GLP-2 prevented the usual prolonged permeability defect and reduced the number of inflammatory cells in the mucosa. Our studies demonstrate that a single treatment of sensitized mice with GLP diminishes both immediate and late phase hypersensitivity reactions characteristic of food allergy by inhibiting transepithelial uptake of antigen.
This article has been cited by other articles:
![]() |
S. Baldassano, S. Liu, M.-H. Qu, F. Mule, and J. D. Wood Glucagon-like peptide-2 modulates neurally evoked mucosal chloride secretion in guinea pig small intestine in vitro Am J Physiol Gastrointest Liver Physiol, October 1, 2009; 297(4): G800 - G805. [Abstract] [Full Text] [PDF] |
||||
![]() |
P D Cani, S Possemiers, T Van de Wiele, Y Guiot, A Everard, O Rottier, L Geurts, D Naslain, A Neyrinck, D M Lambert, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability Gut, August 1, 2009; 58(8): 1091 - 1103. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. W. Moran, F. C. Leslie, S. E. Levison, and J. T. McLaughlin Review: Enteroendocrine cells: Neglected players in gastrointestinal disorders? Therapeutic Advances in Gastroenterology, July 1, 2008; 1(1): 51 - 60. [Abstract] [PDF] |
||||
![]() |
E. M Sinclair and D. J. Drucker Proglucagon-Derived Peptides: Mechanisms of Action and Therapeutic Potential Physiology, October 1, 2005; 20(5): 357 - 365. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |